Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Caelyx demonstrates efficacy, reduced cardiac toxicity
April 6th, 2004
Schering-Plough Europe reported that results of a randomized phase III clinical study demonstrated that Caelyx (pegylated liposomal doxorubicin hydrochloride) provided comparable efficacy in the first-line treatment of metastatic breast cancer with significantly reduced cardiac toxicity compared to conventional doxorubicin, one of the most active drugs in the treatment of breast cancer. The study results were published in the Annals of Oncology. "These results with Caelyx in the treatment of metastatic breast cancer represent an important advance in chemotherapy, where significant reductions in side effects such as hair loss, nausea, and...
Source: Cancer Weekly (2004-04-06)
|
